ArticlePharmacoEconomics - open2019

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada.

Peter L Quon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.